Diamyd Medical’s US subsidiary, Diamyd Inc develops products based on the NTDDS-platform (nerve targeting drug delivery system). NTDDS is a system that can deliver therapeutics directly to the
Seroquel XR and Seroquel have been approved for the treatment of major depressive episodes in bipolar disorder. Additionally, Seroquel XR has been licensed for moderate to severe manic
The purpose-built, 15,000 square feet facility expands Icon Central Laboratories’s existing network of laboratories located in Farmingdale, New York; Dublin, Ireland and Singapore. The new laboratory is in
In this role, Dr Wessel will have responsibility for the company’s clinical development and operations, regulatory affairs, biostatistics, data management and drug safety functions. Previously, Dr Wessel was
The Swiss marketing authorization certificate may be used to facilitate regulatory approval and market entry in other countries including Asia and South America. The regulatory dossier to Swissmedic
The tender offer is being made pursuant to a previously announced agreement and plan of merger dated October 29, 2008 among Genelabs, Gemstone and SmithKline Beecham, a wholly-owned
In this newly created role, Dr Brennan will assume responsibility for the company’s MinuteClinic, Accordant Health Care, clinical and medical affairs, and health care strategy. Most recently, Dr
The clinical trial design includes three separate treatment arms examining escalating doses of TH-302, Threshold’s proprietary hypoxia activated prodrug in combination with the chemotherapeutic agents gemcitabine, docetaxel or
On closing, AEterna Zentaris will receive $52.5 million from Cowen Healthcare Royalty Partners (CHRP). In addition, contingent on 2010 net sales of Cetrotide reaching a specified level, AEterna
K2M said that its commitment to a new biomaterials R&D division signals its continued drive to being a market leader in the complex spine market. In furtherance of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.